Atrial Fibrillation: A High-Yield USMLE Review
Atrial fibrillation (AF) is a supraventricular arrhythmia characterized by disorganized atrial activity and an irregularly irregular ventricular response. It is a central Step 1/Step 2 topic because it complicates valvular disease and heart failure, causes embolic stroke from left atrial thrombus, and demands nuanced decisions about rate control, rhythm control, and anticoagulation.
Pathophysiology
Elevated left atrial pressure and stretch — from mitral stenosis obstructing LA-to-LV flow, volume overload in mitral regurgitation, or a stiff, poorly relaxing ventricle in HFpEF — leads to progressive left atrial dilation. The dilated, remodeled atrium generates disorganized electrical activity, so coordinated atrial contraction is lost and the AV node is bombarded with irregular impulses, producing the irregularly irregular ventricular rhythm. Loss of atrial 'kick' plus blood stasis in the fibrillating atrium promotes thrombus formation, which explains the high embolic/stroke risk.
Presentation
- Palpitations — a classic complaint, frequently seen in mitral stenosis, mitral regurgitation, and heart failure
- Irregularly irregular pulse on examination (e.g., an elderly patient with HR that is irregular/irregularly irregular)
- Dyspnea and fatigue, particularly when rapid ventricular response shortens diastolic filling time
- Systemic embolism, including stroke, from left atrial thrombus — the feared complication
- Vague presentations in older adults (e.g., 'weakness' or 'just isn't herself'), which carry a high lethality budget and warrant a disciplined workup
Diagnosis
- ECG: irregularly irregular rhythm; in the setting of WPW, AF appears as an irregular, wide-complex tachycardia with very rapid rates (up to ~280 bpm) due to conduction over the accessory pathway
- Echocardiography: identifies underlying structural causes such as mitral stenosis, mitral regurgitation, LA dilation, and LV hypertrophy/HFpEF; can assess for LA thrombus and guide surgical/anticoagulation decisions
- BNP/NT-proBNP: levels are elevated by atrial fibrillation itself, a confounder to remember when interpreting heart failure biomarkers
Management
- Rate control with AV nodal agents — beta-blockers or calcium channel blockers to prolong diastole; digoxin is also used (watch for toxicity, especially with renal impairment)
- Anticoagulation to prevent embolic stroke: use CHA2DS2-VASc to guide therapy in non-valvular AF; in mitral stenosis with AF, anticoagulate with warfarin (target INR 2–3) regardless of score, because thromboembolic risk is very high and DOACs are not validated in this valvular AF
- Rhythm control with electrical cardioversion or antiarrhythmics; sotalol (a class III agent) must be initiated inpatient with continuous telemetry, monitoring QTc after each dose and stopping/reducing if QTc exceeds 500 ms
- WPW with AF: perform electrical cardioversion if unstable, or use procainamide (slows accessory-pathway conduction) — never AV nodal blockers
High-yield
- Irregularly irregular pulse is the classic bedside finding of AF
- Mitral stenosis + AF = anticoagulate with warfarin ALWAYS, independent of CHA2DS2-VASc; DOACs are not validated for valvular AF from MS
- WPW + AF (irregular, wide-complex tachycardia): AV nodal blockers — adenosine, beta-blockers, calcium channel blockers, digoxin — are contraindicated because they force conduction down the accessory pathway and can degenerate to VF; treat with procainamide or cardioversion
- Sotalol prolongs the QT interval and risks Torsades de Pointes, so it requires inpatient initiation with telemetry, especially with renal impairment, hypokalemia, or hypomagnesemia
- AF raises BNP/NT-proBNP levels, an important confounder in heart failure evaluation
- AF is characteristic of HFpEF (the atria struggle against a stiff ventricle) and marks decompensation in chronic MR
Pitfalls
- Applying CHA2DS2-VASc to valvular AF: the score was developed for non-valvular AF and does not apply to rheumatic mitral stenosis, where anticoagulation is always indicated
- Giving AV nodal blocking agents in WPW-associated AF — this removes the AV node 'safety valve,' accelerates ventricular rate, and can precipitate VF
- Using a DOAC in a patient with mitral stenosis and AF, where warfarin is the validated agent
- Reassurance from a 'normal' anticoagulation status without checking adequacy — e.g., a subtherapeutic INR (1.5) on warfarin who develops new VTE requires bridging with parenteral anticoagulation or switching to a DOAC
- Overlooking digoxin toxicity in AF patients when renal function declines — precipitants like hypokalemia and worsening renal clearance can tip a stable patient into toxicity without any dose change
Don't just memorize Atrial Fibrillation — practice reasoning through it on branching cases where your decisions shape the patient.